Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
In the realms of biotech investing, the comparison between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) presents a compelling dilemma for 2026. Axsome specializes in neuroscience, offering products for central nervous system disorders such as Auvelity for major depressive disorder and Sunosi for narcolepsy. The company's growth trajectory is being propelled by the FDA approval of Symbravo for migraine treatment in 2025, and through licensing agreements with entities like Pharmanovia, Axsame aims to expand its presence in Europe and the Middle East.
On the other hand, Moderna's expansive platform is built on the versatile messenger RNA technology that has revolutionized vaccine development, particularly for infectious diseases. The company is now diversifying its portfolio into oncology and rare diseases, leveraging its existing success with COVID-19 vaccines to explore new frontiers.
However, Moderna is currently undergoing a period of transition, which may influence its stock performance in the coming years. Investors must weigh these strategic differences to determine which biotech stock presents a more favorable investment opportunity in 2026.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
